Poxel Provides 1Q16 Cash Figures
LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of novel products to treat type 2 diabetes, today announced its cash position for the first quarter 2016.
As of March 31, 2016, unaudited cash and cash equivalents were €37.3 million, as compared to €32.8 million as of March 31, 2015.
As expected, Poxel did not generate significant revenues in either the first quarter of 2016 or 2015.
As of March 31, 2016, unaudited cash and cash equivalents were €37.3 million, as compared to €32.8 million as of March 31, 2015.
As expected, Poxel did not generate significant revenues in either the first quarter of 2016 or 2015.